Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus HYDRO RESERP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL 15 versus HYDRO RESERP.
ALDORIL 15 vs HYDRO-RESERP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
50-100 hours (terminal); prolonged in renal impairment, leading to accumulation on repeated dosing.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Renal: 30-40% as unchanged reserpine; biliary/fecal: 60-70% as metabolites.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination